Inhibrx Biosciences (NASDAQ:INBX) Stock Price Up 8.6% – Time to Buy?

Inhibrx Biosciences, Inc. (NASDAQ:INBX)’s stock price traded up 8.6% during mid-day trading on Tuesday . The stock traded as high as $114.00 and last traded at $114.0170. Approximately 135,732 shares traded hands during trading, a decline of 57% from the average daily volume of 312,245 shares. The stock had previously closed at $104.94.

More Inhibrx Biosciences News

Here are the key news stories impacting Inhibrx Biosciences this week:

• Positive Sentiment: HC Wainwright began coverage of Inhibrx Biosciences with a Buy rating and a $245 price target, substantially above the stock’s recent trading level. The firm’s bullish stance is the primary apparent catalyst for the stock’s advance. HC Wainwright Begins Coverage on Inhibrx Biosciences
• Positive Sentiment: HC Wainwright forecasts a narrower loss over time, estimating a loss of $8.93 per share for fiscal 2026 and $8.47 per share for fiscal 2027. Its quarterly estimates range from losses of $2.14 to $2.30 per share in late 2026 and $2.02 to $2.22 per share in 2027, suggesting gradual improvement in earnings performance.
• Neutral Sentiment: Reported short-interest data showed 0 shares sold short as of August 25, unchanged from the prior report. With a zero short-interest ratio, the data provides no meaningful indication of short-covering activity or bearish positioning.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Citigroup reiterated a “market perform” rating on shares of Inhibrx Biosciences in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibrx Biosciences in a research note on Tuesday, June 16th. Wall Street Zen lowered Inhibrx Biosciences from a “hold” rating to a “strong sell” rating in a research report on Monday, August 17th. Finally, HC Wainwright initiated coverage on Inhibrx Biosciences in a research report on Monday. They set a “buy” rating and a $245.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $197.50.

Inhibrx Biosciences Trading Up 2.1%

The company has a current ratio of 5.07, a quick ratio of 5.07 and a debt-to-equity ratio of 12.58. The company has a market cap of $1.84 billion, a PE ratio of -14.11 and a beta of 3.51. The business’s 50-day simple moving average is $93.07 and its 200-day simple moving average is $90.11.

Inhibrx Biosciences (NASDAQ:INBX) last issued its earnings results on Thursday, August 13th. The company reported ($2.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.28) by ($0.06). As a group, analysts expect that Inhibrx Biosciences, Inc. will post -9.91 EPS for the current fiscal year.

Institutional Trading of Inhibrx Biosciences

A number of institutional investors have recently bought and sold shares of INBX. Persistent Asset Partners Ltd acquired a new position in Inhibrx Biosciences in the 4th quarter worth about $27,000. Strs Ohio acquired a new stake in shares of Inhibrx Biosciences during the 1st quarter valued at about $27,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Inhibrx Biosciences during the 3rd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Inhibrx Biosciences by 26.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 707 shares of the company’s stock valued at $56,000 after buying an additional 147 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of Inhibrx Biosciences by 71.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,886 shares of the company’s stock valued at $64,000 after buying an additional 789 shares in the last quarter. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need.

The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration.